GO
Loading...

Allergan Inc

More

  • Early movers: DSW, BABA, EBAY, RTN, AAPL & more Tuesday, 17 Mar 2015 | 7:56 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • After-hours buzz: Jumei, American Air & more Monday, 16 Mar 2015 | 5:46 PM ET
    Traders on the floor of the New York Stock Exchange.

    Take a look at some of Monday's after-hours buzz: Jumei, American Air & more.

  • Valeant won't overpay for Salix: Bill Ackman Friday, 13 Mar 2015 | 12:33 PM ET
    Valeant Pharmaceuticals International’s headquarters in Mississauga, Ontario, Canada, is shown in this March 30, 2011 photo.

    Valeant chief Michael Pearson won't pay too much for Salix, which earlier this week received a competing offer from Endo, Bill Ackman tells CNBC.

  • In a letter released on Wednesday, the organization urged Health and Human Services Secretary Sylvia Burwell to withdraw the proposal, saying pharmaceutical companies could "sell more drugs by making them seem safer than FDA has judged them to be." The FDA said it would allow distribution of new information in medical journals showing that the severity or...

  • Activists give hedge funds best returns in a year Tuesday, 10 Mar 2015 | 9:15 AM ET
    Bill Ackman

    Hedge funds are back in the black for 2015 and some familiar strategies are leading the way.

  • Early movers: QCOM, CS, URBN, SWKS, PG & more Tuesday, 10 Mar 2015 | 7:49 AM ET

    Some of the names on the move ahead of the open.

  • Ackman's $20 billion Pershing Square Capital Management hedge fund began building up the $3.3 billion stake, only months after its vocal effort to help Valeant buy Botox-maker Allergan failed, a source familiar with the investment told Reuters. His Pershing Square has notched big wins at railway firm Canadian Pacific and shopping mall operator General...

  • March 9- An injection for double chin reduction developed by Kythera Biopharmaceutical Inc was unanimously backed by an independent panel of experts on Monday, bringing the drug a step closer to approval by the U.S. Food and Drug Administration. The FDA typically accepts the panel's recommendations. The drug is widely expected to win approval by May 13, when the...

  • Ackman's $20 billion Pershing Square Capital Management began building up the 5 percent stake in the Canadian drug maker this year, only months after his vocal effort to help Valeant buy Botox-maker Allergan failed. His Pershing Square has notched big wins at railway Canadian Pacific and shopping mall operator General Growth Properties, and also made money...

  • Activis' massive bond books said to top $65B Tuesday, 3 Mar 2015 | 10:11 AM ET
    Actavis pharmaceuticals

    Books on Actavis' jumbo nine-tranche bond partly backing the acquisition of Allergan were heard topping $65 billion and are due to close at 1:30 p.m. ET.

  • Cramer: Fastest growing major pharma headed higher Monday, 23 Feb 2015 | 6:45 PM ET
    Valeant Pharmaceuticals sign at the company's headquarters in Mississauga, Ontario.

    This major pharmaceutical company just announced a huge deal. Jim Cramer thinks this is just the beginning.

  • Hedgies all-in on stocks; here's how to play it Monday, 23 Feb 2015 | 1:19 PM ET
    Traders on the floor of the New York Stock Exchange.

    Allocations in the industry have turned to their most bullish positions ever, with a net-long exposure of 57 percent.

  • NEW YORK, Feb 22- Canada's Valeant Pharmaceuticals International Inc. agreed to acquire gastrointestinal drugmaker Salix Pharmaceuticals Ltd. in an all-cash deal valued at about $10.1 billion, the two companies said on Sunday. The deal is the largest ever for Laval, Quebec- based Valeant, which lost a take-over contest for Allergan Inc last year.

  • Drugmaker Valeant to buy Salix: Sources Saturday, 21 Feb 2015 | 2:55 PM ET

    The all-cash deal could be announced as soon as Sunday, according to these sources who requested not to be identified.

  • NEW YORK, Feb 20- Valeant Pharmaceuticals International Inc is close to a deal to acquire bowel drug maker Salix Pharmaceuticals Ltd for around $160 per share, according to a person directly familiar with the matter. A deal of that size would be the largest ever for Valeant, which lost a takeover contest for Allergan Inc last year. The usually acquisitive Valeant...

  • Forget Buffett. Follow these top investors Wednesday, 18 Feb 2015 | 12:46 PM ET
    Jeffrey Smith, Starboard Value

    CNBC.com found the best performing investors you probably have never heard of, but are beating the market these days. Here are their top picks.

  • NEW YORK, Feb 18- Actavis Plc, a generic drugmaker that has been steadily acquiring branded medicines, said it will change its name to Allergan Inc after it completes its planned $66 billion purchase of the Botox maker, signaling its growing focus on patent-protected drugs. Actavis, which began as a New Jersey- based generics company called Watson, took its current...

  • UPDATE 2-Actavis beats profit estimates, raises forecast Wednesday, 18 Feb 2015 | 9:11 AM ET

    Feb 18- Actavis Plc posted a better-than-expected adjusted quarterly profit and raised its full-year earnings forecast, saying it expected strong sales of its new branded drugs. Actavis agreed to buy Allergan Inc last November for $66 billion, outbidding a hostile offer by activist investor William Ackman and Valeant Pharmaceuticals International Inc.

  • Actavis to take Allergan name   Wednesday, 18 Feb 2015 | 7:42 AM ET
    Actavis to take Allergan name

    Actavis President & CEO Brent Saunders explains the new corporate name, and the strong earnings beat. "We keep surprising people," says Saunders.

  • Actavis, which bought Botox-maker Allergan Inc in November, makes drugs from research in its own pipeline, and copy cat versions of other popular drugs. Sales of the Actavis's branded drugs nearly tripled to $1.83 billion in North America in the fourth quarter, accounting for 45 percent of total revenue. For the fourth quarter ended Dec. 31, Actavis's net loss...